Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)

Trial Profile

Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEOPAC
  • Most Recent Events

    • 02 Feb 2012 Planned end date changed from 1 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov (NCT01521702).
    • 02 Feb 2012 Planned end date changed from 1 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov (NCT01521702).
    • 19 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top